Adjuvant aumolertinib in resected EGFR-mutated non-small cell lung cancer: A multiple-center real-world experience

被引：0
|
作者：
Zhang, Q. [1 ]
Ke, L. [1 ]
Huang, S. [2 ]
Yang, Y. [1 ]
He, T. [1 ]
Sun, H. [3 ]
Wu, Z. [1 ]
Zhang, X. [4 ]
Zhang, H. [5 ]
Lv, W. [1 ]
Hu, J. [1 ]
机构：
[1] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Thorac Surg, Hangzhou, Peoples R China
[2] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Thorac Surg, Hangzhou, Peoples R China
[3] Zhejiang Univ, Taizhou Hosp, Dept Thorac Surg, Taizhou, Peoples R China
[4] Wenzhou Med Univ, Affiliated Hosp 1, Dept Thorac Surg, Wenzhou, Peoples R China
[5] Sci Grp Cent Med, Dept Med Oncol, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
98P
引用
收藏
页码：S98 / S98
页数：1
相关论文
共 50 条
  • [1] Furmonertinib as adjuvant therapy for elderly patients in resected EGFR-mutated non-small cell lung cancer: A double-center, real-world experience
    Wu, Z.
    Zhang, Q.
    He, Z.
    Ke, L.
    He, T.
    Lv, W.
    Hu, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S1655 - S1655
  • [2] Adjuvant Aumolertinib in Resected EGFR-Mutated Non-Small Cell Lung Cancer: Impact on Residual GGO Lesions
    Ma, H.
    Huang, H.
    Feng, Y.
    Chen, S.
    Li, G.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S559 - S560
  • [3] Aumolertinib as adjuvant therapy in postoperative EGFR-mutated non-small cell lung cancer
    Zhang, Q.
    He, C.
    He, T.
    Wang, Y.
    Lv, W.
    Hu, J.
    ANNALS OF ONCOLOGY, 2022, 33 : S73 - S73
  • [4] Adjuvant osimertinib for resected EGFR-mutated non-small cell lung cancer: a game-changer?
    Patel, Shruti R.
    Neal, Joel W.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (07) : 1631 - 1635
  • [5] Clinical efficacy and safety analysis of aumolertinib in real-world treatment of EGFR-mutated advanced non-small-cell lung cancer
    Zhang, Xiaojuan
    Zhang, Mina
    Du, Xinyang
    Zhang, Guowei
    Niu, Yuanyuan
    Wei, Chunhua
    Guo, Lanwei
    Shi, Chao
    Liu, Hangfan
    Wang, Huijuan
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [6] Optimizing adjuvant therapy in EGFR-mutated non-small cell lung cancer
    Shepherd, Annemarie F.
    Preeshagul, Isabel R.
    Shaverdian, Narek
    Wu, Abraham J.
    Gelblum, Daphna Y.
    Gomez, Daniel R.
    Rimner, Andreas
    Simone, Charles B., II
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (23)
  • [7] Furmonertinib treatment in patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastases: A real-world study
    Chen, H.
    Wang, L.
    Wu, Y.
    Wu, Y.
    Ma, S.
    Sen, Y.
    Zhen, H.
    Mo, Y.
    Zhang, C.
    Wang, Q.
    ANNALS OF ONCOLOGY, 2023, 34 : S1697 - S1697
  • [8] Adjuvant Osimertinib in Resected EGFR-Mutated Stage IBeIIIA Non-Small Cell Lung Cancer: Updated ADAURA Results
    Herbst, R. S.
    Wu, Y. -L.
    Grohe, C.
    John, T.
    Majem, M.
    Wang, J.
    Kato, T.
    Goldman, J. W.
    Kim, S. -W.
    Yu, C. -J.
    Vu, H. V.
    Mukhametshina, G.
    Akewanlop, C.
    de Marinis, F.
    Shepherd, F. A.
    Urban, D.
    Stachowiak, M.
    Bolanos, A.
    Huang, X.
    Tsuboi, M.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : E4 - E4
  • [9] Radiotherapy with continued EGFR-TKIs for oligoprogressive disease in EGFR-mutated non-small cell lung cancer: A real-world study
    Hu, Chunhong
    Wu, Sixuan
    Deng, Renfang
    Wu, Yuanqiang
    Pan, Yue
    Shu, Long
    Wu, Fang
    CANCER MEDICINE, 2023, 12 (01): : 266 - 273
  • [10] Aumolertinib as Neoadjuvant Therapy for EGFR-mutated Non-Small Cell Lung Cancer: A Subcohort Analysis of the PURPOSE Trial
    Wang, Y. -Y.
    Gu, Z. -T.
    Bao, F. -C.
    Mao, T.
    Ji, C. -Y.
    Fang, W. -T.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S565 - S565
12345